<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503254</url>
  </required_header>
  <id_info>
    <org_study_id>P2R-REXC-06-EU</org_study_id>
    <secondary_id>P2R-REXC-06-EU</secondary_id>
    <nct_id>NCT02503254</nct_id>
  </id_info>
  <brief_title>Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.</brief_title>
  <official_title>A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) Compared to Continuing to Use Conventional Cigarettes During 5 Days in Confinement.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the study is to demonstrate the reduction of biomarkers of exposure
      (BoExp) to selected harmful and potentially harmful constituents (HPHCs) in adult smokers
      switching for 5 days from conventional cigarette (CC) to Carbon Heated Tobacco Product 1.0
      (CHTP 1.0) as compared to smokers continuing to use CC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of S-phenylmercapturic Acid (S-PMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Carboxyhemoglobin (COHb)</measure>
    <time_frame>5 days</time_frame>
    <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>CHTP 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHTP 1.0</intervention_name>
    <description>CHTP 1.0 ad libitum for 5 days in confinement</description>
    <arm_group_label>CHTP 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Cigarette (CC)</intervention_name>
    <description>Subject's own preferred brand of CC ad libitum for 5 days in confinement</description>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is aged ≥ 21 years.

          -  Subject is Caucasian.

          -  Subject is healthy, as judged by the Investigator.

          -  Subject smokes at least 10 commercially available non-menthol CCs per day (no brand
             restrictions) for at least the last 6 weeks prior to admission, based on
             self-reporting.

          -  Subject has smoked at least for the last 3 years.

          -  Subject does not plan to quit smoking in the next 3 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of the
             medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2)
             or cytochrome P450 2A6 (CYP2A6) activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarzyna Jarus-Dziedzic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioVirtus Research Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. z o.o.</name>
      <address>
        <city>Kajetany</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <results_first_submitted>November 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Modified risk tobacco product</keyword>
  <keyword>Conventional cigarette</keyword>
  <keyword>Reduced exposure</keyword>
  <keyword>Confinement</keyword>
  <keyword>Carbon Heated Tobacco Product</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated (first subject screened): 04 July 2015
At admission (Day -3), all the subjects performed a product trial of the CHTP 1.0. During the baseline period, they continued smoking their single preferred brand of CC. Then, on Day -1, subjects were randomized to one of the two study arms (CHTP 1.0 or CC) in a 1:1 ratio.</recruitment_details>
      <pre_assignment_details>Enrolled and randomized population = 80 subjects
41 subjects in CHTP 1.0 arm
39 subjects in CC arm
Number of subjects enrolled but NOT randomized (who tried the CHTP 1.0 at Day -3) = 5</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CHTP 1.0</title>
          <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
        </group>
        <group group_id="P2">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study population consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC), and at least 1 valid non-safety assessment.
80 randomized subjects: 41 in CHTP 1.0 and 39 in CC study arms. All the randomized subjects completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>CHTP 1.0</title>
          <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
        </group>
        <group group_id="B2">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="10.45"/>
                    <measurement group_id="B2" value="32.7" spread="10.97"/>
                    <measurement group_id="B3" value="33.5" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Organization for Standardization (ISO) nicotine level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>≤ 0.6 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 0.6 to ≤ 1 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</title>
        <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.0</title>
            <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)</title>
          <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares (LS) means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
          <units>pg/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.08" lower_limit="282.39" upper_limit="378.84"/>
                    <measurement group_id="O2" value="1903.61" lower_limit="1637.48" upper_limit="2212.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for CHTP 1.0 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for CHTP 1.0 and CC, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at a two-sided alpha level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on MHBMA levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Reduction</param_type>
            <param_value>82.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.79</ci_lower_limit>
            <ci_upper_limit>86.09</ci_upper_limit>
            <estimate_desc>Geometric LS Mean Reduction = 100 - (CHTP 1.0 : CC ratio)
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
        <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.0</title>
            <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
          <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
          <units>ng/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.27" lower_limit="432.13" upper_limit="498.80"/>
                    <measurement group_id="O2" value="1272.96" lower_limit="1182.66" upper_limit="1370.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for CHTP 1.0 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for CHTP 1.0 and CC, respectively</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at a two-sided alpha level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on 3-HPMA levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Reduction</param_type>
            <param_value>63.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.55</ci_lower_limit>
            <ci_upper_limit>67.12</ci_upper_limit>
            <estimate_desc>Geometric LS Mean Reduction = 100 - (CHTP 1.0 : CC ratio)
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
        <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.0</title>
            <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
          <description>Concentrations measured on Day 5 in urine, adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population.
The FAS consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.</population>
          <units>pg/mg creat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.39" lower_limit="321.26" upper_limit="386.54"/>
                    <measurement group_id="O2" value="2971.98" lower_limit="2703.14" upper_limit="3267.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for CHTP 1.0 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for CHTP 1.0 and CC, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at a two-sided alpha level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on MHBMA levels with product, sex, cigarette consumption, and baseline value as covariates</method_desc>
            <param_type>Geometric LS Mean Reduction</param_type>
            <param_value>88.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.46</ci_lower_limit>
            <ci_upper_limit>89.62</ci_upper_limit>
            <estimate_desc>Geometric LS Mean Reduction = 100 - (CHTP 1.0 : CC ratio)
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Carboxyhemoglobin (COHb)</title>
        <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>5 days</time_frame>
        <population>The analysis was performed on the full analysis set (FAS) population: all randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.
However, due to sample issues such as clotting, COHb assessment results could not be generated for some of the subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.0</title>
            <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Carboxyhemoglobin (COHb)</title>
          <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>The analysis was performed on the full analysis set (FAS) population: all randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC) and had at least 1 non-safety assessment.
However, due to sample issues such as clotting, COHb assessment results could not be generated for some of the subjects.</population>
          <units>percentage of saturation of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.660" lower_limit="2.316" upper_limit="3.054"/>
                    <measurement group_id="O2" value="6.460" lower_limit="5.531" upper_limit="7.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis to be tested is that the geometric mean level on Day 5 of the biomarker of exposure for CHTP 1.0 is lower relative to CC.
Analysis of the BoExp was conducted on the natural log scale in order to test the following hypothesis (one sided test with 2.5% type I error probability):
Null hypothesis (H0): m1≥m2
Alternative hypothesis (H1): m1&lt;m2 Where m1 and m2 are the geometric means of the BoExp levels on Day 5 for CHTP 1.0 and CC respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The primary endpoints were tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model on COHb levels with product, sex, cigarette consumption, and baseline value as covariates.</method_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>58.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.30</ci_lower_limit>
            <ci_upper_limit>66.56</ci_upper_limit>
            <estimate_desc>Geometric LS Mean Reduction = 100 - (CHTP 1.0 : CC ratio)
Expressed as %</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the informed consent form signature until the end of the safety follow-up period, up to 58 days (including a screening period of up to 42 days, a 9-day confinement period followed by a 7-day safety follow-up period (7 days after discharge of the subject or early discontinuation)).</time_frame>
      <desc>The safety was assessed in the safety population, consisting of 85 subjects: 80 randomized subjects (41 in CHTP 1.0 and 39 in CC) and 5 subjects exposed to CHTP 1.0 during the product trial on Day -3 but not randomized.</desc>
      <group_list>
        <group group_id="E1">
          <title>CHTP 1.0</title>
          <description>Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement</description>
        </group>
        <group group_id="E2">
          <title>Conventional Cigarette (CC)</title>
          <description>Ad libitum use of subject's own preferred brand of CC for 5 days in confinement</description>
        </group>
        <group group_id="E3">
          <title>Enrolled But Not Randomized</title>
          <description>Subjects who tried the CHTP 1.0 at Admission (Day -3) but were not randomized</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Concussion was considered to be moderate in intensity and not related to the CHTP 1.0 or CC but to study procedures. This serious adverse event was considered to have resolved after 4 days. The subject had no ongoing medical conditions at Screening</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belongs to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cam Tuan Tran</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 (58) 242 2620</phone>
      <email>CamTuan.Tran@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

